Highlights

• ncRNAs, including miRNAs and lncRNAs, are deregulated in RA and significantly impact disease pathogenesis and progression.
• Specific ncRNAs can serve as biomarkers for RA diagnosis, predict responses to treatment, and monitor disease activity.
• While preclinical findings are encouraging, the clinical efficacy of ncRNAs as therapeutic targets in RA awaits further confirmation.

Summary

This research paper discusses the role of non-coding RNAs (ncRNAs), including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), in managing rheumatoid arthritis (RA). The discovery of ncRNAs has shed light on their involvement in RA pathogenesis, progression, and treatment.

This paper also underscores the challenges in early RA diagnosis and the limitations of current treatments such as methotrexate (MTX), which can be ineffective for some patients. This leads to the need for better diagnostic and treatment strategies.

NcRNAs are crucial for regulating inflammatory responses and the pathogenesis of RA. Moreover, they also serve as potential biomarkers for identifying high-risk patients, guiding treatment plans, and evaluating therapeutic outcomes.

This finding highlights the significant impact of genetic variations in ncRNA genes on RA risk and disease mechanisms. These findings suggest that monitoring ncRNA levels could aid in early diagnosis, therapeutic decision-making, and predicting treatment responses.

J. Yang et al., “The role of non-coding RNAs (miRNA and lncRNA) in the clinical management of rheumatoid arthritis,” Pharmacological Research, vol. 186, p. 106549, Dec. 2022, doi: